$2.01
1.01% yesterday
Nasdaq, Jun 11, 10:00 pm CET
ISIN
US05479K1060
Symbol
ELUT
Sector
Industry

Aziyo Biologics Inc - Ordinary Shares - Class A Stock price

$2.01
+0.19 10.44% 1M
-2.00 49.88% 6M
-1.73 46.26% YTD
-1.96 49.31% 1Y
-14.99 88.18% 5Y
-14.99 88.18% 10Y
-14.99 88.18% 20Y
Nasdaq, Closing price Wed, Jun 11 2025
+0.02 1.01%
ISIN
US05479K1060
Symbol
ELUT
Sector
Industry

Key metrics

Market capitalization $82.64m
Enterprise Value $89.54m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.94
P/S ratio (TTM) P/S ratio 2.72
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 4.86%
Revenue (TTM) Revenue $30.41m
EBIT (operating result TTM) EBIT $-29.63m
Free Cash Flow (TTM) Free Cash Flow $-29.81m
Cash position $17.36m
EPS (TTM) EPS $-1.49
P/E forward negative
P/S forward 2.88
EV/Sales forward 3.12
Short interest 0.26%
Show more

Is Aziyo Biologics Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,840 stocks worldwide.

Aziyo Biologics Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Aziyo Biologics Inc - Ordinary Shares - Class A forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Aziyo Biologics Inc - Ordinary Shares - Class A forecast:

Buy
100%

Financial data from Aziyo Biologics Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
30 30
5% 5%
100%
- Direct Costs 17 17
15% 15%
57%
13 13
50% 50%
43%
- Selling and Administrative Expenses 38 38
36% 36%
125%
- Research and Development Expense 4.69 4.69
10% 10%
15%
-26 -26
31% 31%
-86%
- Depreciation and Amortization 3.46 3.46
5% 5%
11%
EBIT (Operating Income) EBIT -30 -30
26% 26%
-97%
Net Profit -58 -58
21% 21%
-190%

In millions USD.

Don't miss a Thing! We will send you all news about Aziyo Biologics Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aziyo Biologics Inc - Ordinary Shares - Class A Stock News

Neutral
GlobeNewsWire
15 days ago
— Innovative approach accelerates new product development and testing — — Innovative approach accelerates new product development and testing —
Neutral
Seeking Alpha
about one month ago
Elutia Inc. (NASDAQ:ELUT ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Matt Steinberg - FINN Partners Randal Mills - Chief Executive Officer Matt Ferguson - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Matt Park - Cantor Fitzgerald Operator Good afternoon, ladies and gentlemen. Welcome to the Elutia First Quarter 2025...
Neutral
GlobeNewsWire
about one month ago
- New Boston Scientific distribution partnership now underway - - Conference call today at 5:00 p.m. ET / 2:00 p.m.
More Aziyo Biologics Inc - Ordinary Shares - Class A News

Company Profile

Aziyo Biologics, Inc. operates as a biotechnology company which focuses on regenerative medicine in areas such as cardiology, orthopedics and other medical specialties. It offers cardiac device envelope, vascular surgery, cardiothoracic repair, orthopedics and spine, sports medicine, dermal, and wound care. The company was founded on August 6, 2015 and is headquartered in Silver Spring, MD.

Head office United States
CEO Charles Mills
Employees 51
Founded 2015
Website elutia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today